Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Jul;166(6):1964–1976. doi: 10.1111/j.1476-5381.2012.01905.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society

PMC Copyright notice

Masson's Trichrome staining of lung samples from ovalbumin-challenged/vehicle-treated mice show significant peribronchial and perivascular fibrosis (B) (n = 6) compared with PBS-challenged mice (A) (n = 6). Treatment with Ang-(1–7) (0.3 mg·kg⁻¹) (C) (n = 6) resulted in a significant reduction in peribronchial and perivascular fibrosis and was similar to in appearance to PBS vehicle group (A). Treatment with A779 (1 mg·kg⁻¹; i.p.) (D) (n = 6) significantly blocked the Ang-(1–7)-induced inhibition of peribronchial and perivascular fibrosis; (), significant and remarkable peribronchial and perivascular fibrosis.

Inline graphic — Masson's Trichrome staining of lung samples from ovalbumin-challenged/vehicle-treated mice show significant peribronchial and perivascular fibrosis (B) (n = 6) compared with PBS-challenged mice (A) (n = 6). Treatment with Ang-(1–7) (0.3 mg·kg⁻¹) (C) (n = 6) resulted in a significant reduction in peribronchial and perivascular fibrosis and was similar to in appearance to PBS vehicle group (A). Treatment with A779 (1 mg·kg⁻¹; i.p.) (D) (n = 6) significantly blocked the Ang-(1–7)-induced inhibition of peribronchial and perivascular fibrosis; (), significant and remarkable peribronchial and perivascular fibrosis.